The U.S. subsidiary of Glenmark Pharmaceuticals will pay Humana nearly $15.3 million in the wake of antitrust and consumer protection lawsuits.
Glenmark disclosed the settlement in an Aug. 11 filing with the National Stock Exchange of India. The document said the company faced allegations of price-fixing, market allocation and anticompetitive behavior in more than 35 complaints. The lawsuits came from purchasers, end-payers and state attorneys general.
Humana waged three of the complaints as part of the consolidated litigation, the filing said. The insurer, among other plaintiffs, accused Glenmark of drug-specific conspiracies and alleged a broader conspiracy among several generic-drug manufacturers in the U.S. The Glenmark subsidiary, as well as other defendants, denied the allegations.
Glenmark’s U.S. company will pay the settlement, which includes interest, in two installments. The company said the settlement will not have a “significant” effect on its finances.
“The settlement makes clear that Glenmark USA denies each and every one of the allegations made against it,” the filing said. “The settlement does not constitute any concession or admission of liability, wrongdoing or illegality on the part of Glenmark USA.”
Glenmark also reached a $29.6 million settlement covering 48 states and territories in July, according to a news release from New Jersey Attorney General Jennifer Davenport.
Becker’s contacted Humana and will update this story if more information becomes available.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
